Vyant Bio (OTCMKTS:VYNT) Trading Up 7.8%

Vyant Bio, Inc. (OTCMKTS:VYNT)’s share price traded up 7.8% on Thursday . The stock traded as high as $0.20 and last traded at $0.19. 19,100 shares were traded during mid-day trading, a decline of 88% from the average session volume of 161,822 shares. The stock had previously closed at $0.18.

Vyant Bio Trading Up 7.8 %

The company has a debt-to-equity ratio of 0.04, a current ratio of 2.86 and a quick ratio of 2.86. The company’s 50 day simple moving average is $0.19 and its two-hundred day simple moving average is $0.19.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Vyant Bio stock. Captrust Financial Advisors increased its position in shares of Vyant Bio, Inc. (OTCMKTS:VYNT) by 405,350.0% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 202,725 shares of the company’s stock after buying an additional 202,675 shares during the period. Captrust Financial Advisors owned 3.45% of Vyant Bio worth $113,000 at the end of the most recent reporting period.

Vyant Bio Company Profile

Vyant Bio, Inc, a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD).